Selective internal radiation therapy in treatment of hepatocellular carcinoma: New concepts of personalization

Personalized Medicine

Volumn 13, Issue 4, 2016, Pages 347-360

  Abraham, Jella Andrea ^a   Yeghiazaryan, Kristina ^a   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

biomarker panel; blood; hepatocellular carcinoma; individual patient profiles; noninvasive methods; patient stratification; predictive preventive personalized medicine; radioresistance; radiosensitivity; selective internal radiation therapy

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; PROGRAMMED DEATH 1 RECEPTOR; REACTIVE OXYGEN METABOLITE;

ADVANCED CANCER; BLOOD ANALYSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CYTOKINE PRODUCTION; DNA DAMAGE; DOSIMETRY; EXTRACELLULAR MATRIX; FOLLOW UP; HEMOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; IONIZING RADIATION; LIVER CELL CARCINOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADIATION HAZARD; RADIOSENSITIVITY; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VASOSPASM;

EID: 84978820201     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme-2016-0014     Document Type: Review

References (113)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87-108 (2015).
2. Abraham JA, Golubnitschaja O. Time for paradigm in hepatocellular carcinoma management: is an advanced approach by predictive, preventive and personalized medicine in horizon? Pers. Med. doi:10.2217/pme-2016-0013 (2016) (Manuscript in press).
3. Bargellini I, Battaglia V, Caramella D, Bortolozzi C. Imaging in hepatocellular carcinoma: radiologic assessment. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Berliner L, Lemke HU (Eds.). Springer International Publishing, Cham, Switzerland, 33-44 (2015).
4. Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2), 497-507 (2011).
5. Salem R, Gilbertsen M, Butt Z et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. 11(10), 1358-1365 (2013).
6. Gramenzi A, Golferi R, Mosconi C et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 35(3), 1036-1047 (2015).
7. SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (SARAH). https://clinicaltrials.gov/ct2/show/NCT01482442
8. Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma. https://clinicaltrials.gov/ct2/show/NCT00846131
9. Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC). https://clinicaltrials.gov/ct2/show/NCT001126645
10. Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB). https://clinicaltrials.gov/ct2/show/NCT01135056
11. Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) (TRACE). https://clinicaltrials.gov/ct2/show/NCT01381211
12. Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery. https://clinicaltrials.gov/ct2/show/NCT00956930
13. Bhangoo MS, Karnani DR, Hein PN et al. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J. Gastrointest. Oncol. 6(5), 469-478 (2015).
14. Ashamalla H, Mattes MD. Radiation oncology in the treatment of hepatocellular carcinoma. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Berliner L, Lemke HU (Eds.), Springer International Publishing, Cham, Switzerland, 93-102 (2015).
15. Fernandez-Ros N, Inarrairaegui M, Paramo JA et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces infammation and endothelial stress and activates coagulation. Liver Int. 35(5), 1590-1596 (2015).
16. Golubnitschaja O, Cebioglu M, Yeghiazaryan K, Pieper C, Schild HH. "Molecular signature" in blood of liver cancer diagnosed patients as a criterion for optimal therapy modalities. EPMA J. 5(Suppl. 1), A38 (2014).
17. Abraham JA, Golubnitschaja O. Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma. EPMA J. 7(Suppl. 1), A1 (2016).
18. Golubnitschaja O, Kinkorova J, Costigliola V Predictive, Preventive and Personalised Medicine as the hardcore of "Horizon 2020": EPMA position paper. EPMA J. 5(1), 6 (2014).
19. Ahmadzadehfar H, Sabet A, Biersack HJ. Radioembolization for the treatment of unresectable hepatocellular carcinoma. In: Hepatocellular Carcinoma-Future Outlook. Kaseb AO (Ed.). InTech, Rijeka, Croatia, 41-62 (2013).
20. Mosconi C, Cappelli A, Pettinato C, Golferi R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J. Hepatol. 7(5), 738-752 (2015).
21. Lam MG, Abdelmaksoud MH, Chang DT et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 87(2), 323-329 (2013).
22. Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization. J. Nucl. Med. 56(8), 1157-1162 (2015).
23. Hipps D, Ausania F, Manas DM, Rose JD, French JJ. Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg. 2013, 570808 (2013).
24. Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur. J. Nucl. Med. Mol. Imaging 43(3), 559-575 (2016).
25. Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. In: Multidisciplinary Treatment of Hepatocellular Carcinoma. Vauthey J-N, Brouquet A (Eds.). Springer Berlin Heidelberg, Germany, 207-224 (2013).
26. Earl TM, Chapman WC. Transplantation for hepatocellular carcinoma: the North American experience. In: Multidisciplinary Treatment of Hepatocellular Carcinoma. Vauthey J-N, Brouquet A (Eds.). Springer Berlin Heidelberg, Germany, 145-164 (2013).
27. Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J. Gastroenterol. 21(28), 8478-8491 (2015).
28. Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 4(1), 12 (2013).
29. Golubnitschaja O, Yeghiazaryan K, Costigliola V et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualifed integrative approach in the horizon? EPMA J. 4(1), 6 (2013).
30. Riaz A, Lewandowski RJ, Kulik LM et al. Complications following radioembolization with Yttrium-90 microspheres: a comprehensive literature review. J. Vasc. Interv. Radiol. 20(9), 1121-1130 (2009).
31. Gil-Alzugaray B, Chopitea A, Inarrairaegui M et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57(3), 1078-1087 (2013).
32. Sangro B, Gil-Alzugaray B, Rodriguez J et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112(7), 1538-1546 (2008).
33. Cheng W, Xiao L, Ainiwaer A et al. Molecular responses of radiation-induced liver damage in rats. Mol. Med. Rep. 11(4), 2592-2600 (2015).
34. Lau WY, Leung WT, Ho S et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial Yttrium-90 microspheres: a Phase I and II study. Br. J. Cancer 70(5), 994-999 (1994).
35. Lau W-Y, Kennedy AS, Kim YH et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 401-407 (2012).
36. Garin E, Lenoir L, Rolland Y et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J. Nucl. Med. 53(2), 255-263 (2012).
37. Mazzaferro V, Sposito C, Bhoori S et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a Phase 2 study. Hepatology 57(5), 1826-1837 (2013).
38. Garin E, Rolland Y, Edeline J et al. Personalized dosimetry with intensifcation using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J. Nucl. Med. 56(3), 339-346 (2015).
39. Barnett GC, Kerns SL, Noble DJ, Dunning AM, West CM, Burnet NG. Incorporating genetic biomarkers into predictive models of normal tissue toxicity. Clin. Oncol. (R. Coll. Radiol.) 27(10), 579-587 (2015).
40. Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity-how important is it? Clin. Oncol. (R. Coll. Radiol.) 8(1), 25-34 (1996).
41. Wang B. Analyzing cell cycle checkpoints in response to ionizing radiation in mammalian cells. Methods Mol. Biol. 1170, 313-320 (2014).
42. Hein AL, Ouellette MM, Yan Y Radiation-induced signaling pathways that promote cancer cell survival (review). Int. J. Oncol. 45(5), 1813-1819 (2014).
43. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15(7), 409-425 (2015).
44. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144(3), 512-527 (2013).
45. Persa E, Balogh A, Safrany G, Lumniczky K. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 368(2), 252-261 (2015).
46. Huber SM, Butz L, Stegen B et al. Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol. 4, 212 (2013).
47. Lumniczky K, Safrany G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett. 356(1), 114-125 (2015).
48. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med. J. 50(5), 601-612 (2009).
49. Wu H, Zhao W, Liu S, Zheng J, Ji G, Xie Y Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary metastases of hepatocellular carcinoma. Int. J. Clin. Exp. Med. 8(1), 1035-1042 (2015).
50. Ji J, Wang XW Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 39(4), 461-472 (2012).
51. Scartozzi M, Faloppi L, Bianconi M et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS ONE 7(3), e32653 (2012).
52. Dayal R, Singh A, Pandey A, Mishra KP. Reactive oxygen species as mediator of tumor radiosensitivity. J. Cancer Res. Ther. 10(4), 811-818 (2014).
53. Kim W, Youn H, Kang C, Youn B. Infammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis 20(9), 1242-1252 (2015).
54. Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol. 20(25), 8082-8091 (2014).
55. Shin SM, Yang JH, Ki SH. Role of the Nrf2-ARE pathway in liver diseases. Oxid. Med. Cell Longev. 2013, 763257 (2013).
56. Carvajal-Yepes M, Himmelsbach K, Schaedler S et al. Hepatitis C virus impairs the induction of cytoprotective Nrf2 target genes by delocalization of small Maf proteins. J. Biol. Chem. 286(11), 8941-8951 (2011).
57. Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV. Cellular oxidative stress response mediates radiosensitivity in Fus1-defcient mice. Cell Death Dis. 6, e1652 (2015).
58. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 38(1), 96-109 (2010).
59. Yang LY, Chen WL, Lin JW et al. Differential expression of antioxidant enzymes in various hepatocellular carcinoma cell lines. J. Cell Biochem. 96(3), 622-631 (2005).
60. Mollbrink A, Jawad R, Vlamis-Gardikas A et al. Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome. Int. J. Immunopathol. Pharmacol. 27(2), 169-183 (2014).
61. Al-Shabrawey M, Smith S. Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J. 1(1), 56-72 (2010).
62. Yeghiazaryan K, Mamlouk S, Trog D et al. Irradiated breast cancer patients demonstrate subgroup-specifc regularities in protein expression patterns of circulating leukocytes. Cancer Genomics Proteomics 4(6), 411-418 (2007).
63. Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fbrosis epidemics. EPMA J. 5(1), 21 (2014).
64. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8 (5), 292-301 (2011).
65. Flamen P, Vanderlinden B, Delatte P et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys. Med. Biol. 53(22), 6591-6603 (2008).
66. Tu T, Budzinska MA, Maczurek AE et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int. J. Mol. Sci. 15 (6), 9422-9458 (2014).
67. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9 (6), 1957-1971 (2003).
68. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22(8), 1178-1182 (2007).
69. Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast Cancer Res. 17, 122 (2015).
70. Wong CC, Tse AP, Huang YP et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 60(5), 1645-1658 (2014).
71. Cox TR, Bird D, Baker AM et al. LOX-mediated collagen crosslinking is responsible for fbrosis-enhanced metastasis. Cancer Res. 73(6), 1721-1732 (2013).
72. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309-322 (2012).
73. Clausson C-M, Grundberg I, Weibrecht I, Nilsson M, Söderberg O. Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments. EPMA J. 3(1), 7 (2012).
74. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin. Cancer Biol. 21(1), 35-43 (2011).
75. Giannelli G, Villa E, Lahn M. Transforming growth factor-p as a therapeutic target in hepatocellular carcinoma. Cancer Res. 74(7), 1890-1894 (2014).
76. Akyol G, Yilmaz G. Stem cell expression profle in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Stem Cell Transl. Investig. 1, e232 (2014).
77. Katoonizadeh A, Poustchi H. Adult hepatic progenitor cell niche: how it affects the progenitor cell fate. Middle East J. Dig. Dis. 6(2), 57-64 (2014).
78. Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136(3), 1012-1024 (2009).
79. + liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315(2), 129-137 (2012).
80. Lui SK, Vilchez V, Gedaly R. Liver cancer stem cells: a new paradigm for hepatocellular carcinoma treatment. J. Stem Cell Res. Ther. 5, 283 (2015).
81. Sainz B, Heeschen C. Standing out from the crowd: cancer stem cells in hepatocellular carcinoma. Cancer Cell 23(4), 431-433 (2013).
82. + liver cancer stem cells. Exp. Cell Res. 319(2), 126-132 (2013).
83. + liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 339(1), 70-81 (2013).
84. Kohga K, Tatsumi T, Takehara T et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 52 (6), 872-879 (2010).
85. Romano M, De Francesco F, Pirozzi G et al. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2(5), 443-456 (2015).
86. + T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 73(8), 2435-2444 (2013).
87. + T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128(4), 887-896 (2011).
88. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239-245 (2007).
89. Bertino G, Demma S, Ardiri A et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res. Int. 2015, 731469 (2015).
90. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
91. Baban B, Liu JY, Zheng M, Lee J, Grochowska K, Mozaffari M. Programmed death-1in cancer stem cells may serve as a novel immunotherapy marker. EPMA J. 5(Suppl. 1), A115 (2014).
92. Muehlbauer M, Fleck M, Schütz C et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and-γ and mediates T cell apoptosis. J. Hepatol. 45(4), 520-528 (2006).
93. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS. Chronically infamed livers up-regulate expression of inhibitory B7 family members. Hepatology 50(5), 1625-1637 (2009).
94. Yu MC, Chen CH, Liang X et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 40(6), 1312-1321 (2004).
95. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687-695 (2014).
96. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 80(6), 1197-1213 (2006).
97. Chen ZY, Wei W, Guo ZX et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br. J. Cancer 110(3), 733-740 (2014).
98. Sheng T, Wang B, Wang SY et al. The relationship between serum interleukin-6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection. Med. Baltim. 94(24), e941 (2015).
99. Kose S, Ersan G, Tatar B, Adar P, Sengel BE. Evaluation of percutaneous liver biopsy complications in patients with chronic viral hepatitis. Eurasian J. Med. 47(3), 161-164 (2015).
100. Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J. Hepatol. 7(26), 2664-2675 (2015).
101. Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH). https://clinicaltrials.gov/ct2/show/NCT01672879
102. Yang ZF, Ngai P, Ho DW et al. Identifcation of local and circulating cancer stem cells in human liver cancer. Hepatology 47(3), 919-928 (2008).
103. Zhou G, Wilson G, George J, Qiao L. Targeting cancer stem cells as a therapeutic approach in liver cancer. Curr. Gene Ther. 15(2), 161-170 (2015).
104. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin. Gastroenterol. Hepatol. 11 (9), 1064-1074 (2013).
105. + regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients. Clin. Chem. Lab. Med. 52(9), 1357-1365 (2014).
106. Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59(1), 81-88 (2013).
107. Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT02311361
108. A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer. https://clinicaltrials.gov/show/NCT01658878
109. Nakamoto N, Cho H, Shaked A et al. Synergistic reversal of intrahepatic HCV-specifc CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5(2), e1000313 (2009).
110. Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 4(1), 2 (2013).
111. Safety and Effcacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). https://clinicaltrials.gov/ct2/show/NCT01672866
112. A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma. https://clinicaltrials.gov/ct2/show/NCT02423343
113. Clinical Trial to Evaluation the Safety and Effcacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). https://clinicaltrials.gov/ct2/show/NCT02462967